


PHARMACEUTICAL 2021



Verastem Inc. Rank 219 of 409







PHARMACEUTICAL 2021



Verastem Inc. Rank 219 of 409

The relative strengths and weaknesses of Verastem Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Verastem Inc. compared to the market average is the variable Revenues, increasing the Economic Capital Ratio by 224% points. The greatest weakness of Verastem Inc. is the variable Other Expenses, reducing the Economic Capital Ratio by 135% points.

The company's Economic Capital Ratio, given in the ranking table, is -153%, being 202% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	144,938
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	17,093
Liabilities, Non-Current	2,931
Other Assets	8,995
Other Compr. Net Income	39
Other Expenses	49,733
Other Liabilities	19,051
Other Net Income	-2,378
Property and Equipment	416
Research and Development	41,376
Revenues	88,516
Selling, General and Administrative Expense	62,755

Output Variable	Value in 1000 USD
Assets	154,349
Liabilities	39,075
Expenses	153,864
Stockholders Equity	115,274
Net Income	-67,726
Comprehensive Net Income	-67,706
Economic Capital Ratio	-153%

